X. Luo

发表

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Frontiers in Oncology.

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

Zhen Zhou, Qiao Liu, Liubao Peng, 2022, Frontiers in Public Health.

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China

Chongqing Tan, Qiao Liu, Liubao Peng, 2020, BMJ Open.

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, X. Luo, 2021, Frontiers in Oncology.

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2019, Clinical Drug Investigation.

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China

Zhen Zhou, Chongqing Tan, Qiao Liu, 2022, Frontiers in Pharmacology.

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

Zhen Zhou, Qiao Liu, X. Luo, 2022, Frontiers in Pharmacology.

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Frontiers in Pharmacology.

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2022, Frontiers in Pharmacology.

First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis

Chongqing Tan, Liubao Peng, X. Wan, 2019, Cancer.

Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness

Qiao Liu, Xiaohui Zeng, Xia Luo, 2022, Frontiers in Public Health.

Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis

Chongqing Tan, Liubao Peng, Lidan Yi, 2021, Clinical Rheumatology.

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China

Chongqing Tan, Liubao Peng, Lidan Yi, 2020, PLoS ONE.

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy

Chongqing Tan, Qiao Liu, X. Luo, 2021, Frontiers in Oncology.

Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Advances in Therapy.

Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer

Chongqing Tan, Qiao Liu, X. Luo, 2021, Advances in Therapy.

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

Chongqing Tan, Qiao Liu, X. Luo, 2022, Frontiers in Pharmacology.

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Qijian Deng, Chongqing Tan, Qiao Liu, 2021, Frontiers in Pharmacology.

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, PloS one.

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer

Chongqing Tan, Qiao Liu, X. Luo, 2021, PloS one.